<DOC>
	<DOCNO>NCT03082937</DOCNO>
	<brief_summary>The primary objective study assess mass balance recovery single dose carbon-14 [ 14C ] -A4250 capsule provide plasma , urine faecal sample metabolite profile structural identification healthy male subject .</brief_summary>
	<brief_title>An Open Label , Single-dose , Single Period ADME Study A4250 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<criteria>1 . Healthy male 2 . Age 30 65 year age 3 . Body mass index 18.0 35.0 kg/m2 , outside range , consider clinically significant investigator 4 . Must willing able communicate participate whole study 5 . Must regular bowel movement ( i.e. , average stool production ≥1 ≤3 stool per day ) 6 . Must provide write informed consent 7 . Must agree use adequate method contraception 1 . Subjects receive IMP clinical research study within previous 3 month prior screen 2 . Subjects study site employee , immediate family member study site sponsor employee 3 . Subjects previously enrol study 4 . History drug alcohol abuse past 2 year 5 . Regular alcohol consumption male &gt; 21 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 6 . Current smoker smoke within last 12 month . A confirm positive urine cotinine test screen admission 7 . Current user ecigarettes nicotine replacement product use product within last 12 month 8 . Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study 9 . Subjects suitable vein multiple venepunctures/cannulation assess investigator screen 10 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 11 . Confirmed positive drug abuse test result screen admission 12 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 13 . Evidence renal impairment screening , indicate estimate creatinine clearance ( CLcr ) &lt; 90 mL/min use CockcroftGault equation 14 . History cardiovascular , renal , hepatic , chronic respiratory GI disease judge investigator 15 . Serious adverse reaction serious hypersensitivity drug formulation excipients 16 . Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active 17 . Donation loss great 400 mL blood within previous 3 month 18 . Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol ) herbal remedy 14 day IMP administration . Exceptions may apply case case basis , consider interfere objective study , agree PI sponsor 's medical monitor . 19 . Failure satisfy investigator fitness participate reason</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>